DNA RNA and Cells

21 Nov 2018 Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity
19 Nov 2018 Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
19 Nov 2018 BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
19 Nov 2018 Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
19 Nov 2018 Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
16 Nov 2018 Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
16 Nov 2018 uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
14 Nov 2018 Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections
13 Nov 2018 Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
13 Nov 2018 Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500
13 Nov 2018 Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
13 Nov 2018 New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation
13 Nov 2018 Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
13 Nov 2018 Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
13 Nov 2018 MolMed and Dompé announce the mutual termination of the license and distribution agreement for Zalmoxis®.
11 Nov 2018 Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Beta-sarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E
10 Nov 2018 Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
09 Nov 2018 Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
08 Nov 2018 NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
08 Nov 2018 REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
08 Nov 2018 Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
08 Nov 2018 Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody
07 Nov 2018 Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
07 Nov 2018 Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia
07 Nov 2018 OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top